Advertisement
UK markets close in 7 hours 7 minutes

  • FTSE 100

    8,346.52
    +32.85 (+0.40%)
     

  • FTSE 250

    20,439.50
    +26.42 (+0.13%)
     

  • AIM

    778.44
    +2.02 (+0.26%)
     

  • GBP/EUR

    1.1610
    -0.0014 (-0.12%)
     

  • GBP/USD

    1.2471
    -0.0039 (-0.31%)
     

  • Bitcoin GBP

    49,991.59
    -987.57 (-1.94%)
     

  • CMC Crypto 200

    1,289.49
    -5.18 (-0.40%)
     

  • S&P 500

    5,187.70
    +6.96 (+0.13%)
     

  • DOW

    38,884.26
    +31.99 (+0.08%)
     

  • CRUDE OIL

    77.29
    -1.09 (-1.39%)
     

  • GOLD FUTURES

    2,313.40
    -10.80 (-0.46%)
     

  • NIKKEI 225

    38,202.37
    -632.73 (-1.63%)
     

  • HANG SENG

    18,331.76
    -147.61 (-0.80%)
     

  • DAX

    18,499.46
    +69.41 (+0.38%)
     

  • CAC 40

    8,122.49
    +46.81 (+0.58%)
     
Money:

How to make a tax-free income

Tips for making money that won't be taxed

Silence Therapeutics to Present at Jefferies London Healthcare Conference

Silence Therapeutics plc
·2-min read

Silence Therapeutics to Present at Jefferies London Healthcare Conference

11 November 2021

LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will present at the Jefferies London Healthcare Conference being held November 16-18, 2021.

The on-demand presentation will be available beginning on Thursday, November 18 at 8:00am GMT / 3:00am ET and can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available on the Company’s website following the conference.

Enquiries:

Silence Therapeutics plc

Gem Hopkins, Head of IR and Corporate Communications

ir@silence-therapeutics.com



Tel: +1 (646) 637-3208

Investec Bank plc (Nominated Adviser and Broker)

Daniel Adams/Gary Clarence

Tel: +44 (0) 20 7597 5970

European PR

Consilium Strategic Communications

Mary-Jane Elliott/ Angela Gray / Chris Welsh

silencetherapeutics@consilium-comms.com

Tel: +44 (0) 20 3709 5700

About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron-loading anemia conditions. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/.